Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terizleotide Injection vs Placebo in Postoperative Hepatocellular Carcinoma
CTR20150871Phase 3Active
- Sponsor
- Sino Biological
- Start
- Dec 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of terizleotide in hepatocellular carcinoma (HCC), sponsored by Sino Biological. Started Dec 2015; status: active.
02
Drugs
terizleotide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20150871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150871.